Sign in
Active, not recruitingNo phase

A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Key facts

Who runs it
Chengdu Kangnuoxing Biopharma,Inc.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
600 people, planned
Started
29 May 2026
Expected to end
Feb 2028
Type of study
Observational
Treatments tested
  • Stapokibart
Record updated
5 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study
  • Physician decision to treat the participant with Stapokibart Injection for CRSwNP (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study

Who cannot take part

  • Known history of allergic reaction to Stapokibart Injection
  • Participants with hematologic malignancies
  • Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study
  • Participants currently or plan participating in any interventional clinical trial
  • Women with pregnant

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with CRSwNP.

The group in the trial

  • Group 1

    Treatment: Stapokibart

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Study of Stapokibart Injection in Patients With CRSwNP
Record updated
5 June 2026